BookbagBookbag
Healthcare Decisions

Audit AI Healthcare Decisions Before They Affect Patient Care

Ensure AI-driven clinical recommendations, prior authorizations, and triage decisions are evidence-based and patient-safe.

HIPAAFDA guidance on clinical AICMS prior authorization rulesState telehealth laws21st Century Cures ActState prior authorization reform laws

The Problem

Healthcare organizations are deploying AI for prior authorization decisions, clinical decision support, patient triage, and treatment recommendations. These aren't abstract predictions — they directly affect whether a patient gets the medication they need, how quickly they're seen in the ER, or whether their procedure is approved. When an AI system denies a prior authorization without adequate clinical justification, the patient suffers a delayed treatment and the payer faces regulatory action. The stakes are literally life and health.

  • AI prior authorization denials lack the clinical rationale CMS and state laws require
  • Clinical decision support recommendations can't be traced back to evidence
  • Triage algorithms may systematically undertriage certain patient populations
  • No structured process for documenting AI's role in clinical decisions for liability purposes
Evidence Payload
evidence
Patient: 58F, Type 2 DM (A1c: 8.9%), current regimen: metformin 2000mg + glipizide 10mg. Requesting: GLP-1 receptor agon...
policy_context
Step therapy protocol: (1) metformin, (2) sulfonylurea or DPP-4i, (3) GLP-1 RA eligible after failure of two oral agents...
ai_generated_content
DECISION: DENIED — Patient has not completed required step therapy. Recommend trial of DPP-4 inhibitor before GLP-1 RA a...

What Gets Submitted

What gets submitted when a healthcare AI decision is audited

evidence
Patient: 58F, Type 2 DM (A1c: 8.9%), current regimen: metformin 2000mg + glipizide 10mg. Requesting: GLP-1 receptor agonist (semaglutide). BMI: 34.2. Prior trials: metformin (18 months), glipizide (12 months). Labs: eGFR 62, hepatic function normal.
policy_context
Step therapy protocol: (1) metformin, (2) sulfonylurea or DPP-4i, (3) GLP-1 RA eligible after failure of two oral agents. Clinical criteria: A1c > 7.0% after 90 days on step 2 agent. CMS guidelines: prior auth required for GLP-1 RA class. State law: prior auth decision within 72 hours.
ai_generated_content
DECISION: DENIED — Patient has not completed required step therapy. Recommend trial of DPP-4 inhibitor before GLP-1 RA authorization. Appeal rights included.
model_trace
Diagnosis verification → medication history → step therapy check → clinical criteria evaluation → formulary lookup → prior auth determination → letter generation
model_metadata
model: prior-auth-v3.5, confidence: 0.71, clinical_rules_applied: 4, last_validated: 2024-02-15
redacted_fields
patient_name, mrn, date_of_birth, provider_npi, facility_address

How the Gate Works

Step 1

Submit Evidence

AI decision + evidence payload submitted for structured evaluation

Step 2

Review Against Policy

Decision evaluated against Healthcare Decisions regulations and policy context

Step 3

Verdict & Audit Trail

Structured verdict with failure categories, corrections, and immutable audit record

Evaluation Taxonomy

Failure Categories

  • Step therapy requirement misapplied
  • Clinical criteria not met assessment error
  • Missing clinical evidence consideration
  • Guideline version outdated
  • Patient safety concern
  • Inadequate denial explanation

Business Impact

  • Delayed patient treatment
  • CMS audit finding
  • State regulatory action
  • Malpractice liability exposure
  • Patient grievance/appeal volume

Evidence Sufficiency

  • Complete clinical documentation
  • Partial records — missing lab results
  • Critical clinical data unavailable
  • Documentation conflicts with clinical assessment

Example Verdict

verdict: blocked decision_type: prior_authorization failure_categories: [step_therapy_misapplied, clinical_error] primary_failure: step_therapy_misapplied severity: critical business_impact: delayed_patient_treatment EVIDENCE REVIEW diagnosis: Type 2 DM, A1c 8.9% ✓ current_regimen: metformin + glipizide ✓ step_therapy_status: Step 1 (metformin) ✓ COMPLETE Step 2 (sulfonylurea) ✓ COMPLETE (glipizide IS a sulfonylurea) a1c_after_step2: 8.9% > 7.0% threshold ✓ FINDING "AI denied authorization stating patient has not completed step therapy. However, glipizide IS a sulfonylurea (step 2 agent). Patient has completed both required steps with documented failure (A1c 8.9% after 12 months on step 2). Patient QUALIFIES for GLP-1 RA under protocol." CORRECTED DECISION "APPROVED — Step therapy requirements satisfied. Semaglutide authorized per formulary guidelines." AUDIT TRAIL reviewer: sme_clinical_7842 reviewed_at: 2024-06-03T08:17:55Z policy_version: formulary-2024-q2 escalation: auto (denial + confidence < 0.75)

Compliance Frameworks

HIPAAFDA guidance on clinical AICMS prior authorization rulesState telehealth laws21st Century Cures ActState prior authorization reform laws

Frequently Asked Questions

See how Bookbag audits AI decisions

Join the teams shipping safer AI with real-time evaluation, audit trails, and continuous improvement.